We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.98 | -1.96% | 49.05 | 48.99 | 49.03 | 1,189 | 10:22:51 |
From May 2019 to May 2024
By Colin Kellaher
Ligand Pharmaceuticals Inc. (LGND) Monday said it signed a worldwide license agreement for its OmniAb antibody discovery platform with Paris drug maker Sanofi S.A. (SAN.FR, SNY).
The San Diego biopharmaceutical company said Sanofi will pay an undisclosed upfront platform access fee, along with development and regulatory milestone payments and potential royalties on sales of marketed products.
Ligand said it has licensed OmniAb to more than 40 companies around the world.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 02, 2019 11:59 ET (16:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
